In-vivo studies on Transitmycin, a potent Mycobacterium tuberculosis inhibitor

This study involves the in-vitro and in-vivo anti-TB potency and in-vivo safety of Transitmycin (TR) (PubChem CID:90659753)- identified to be a novel secondary metabolite derived from Streptomyces sp (R2). TR was tested in-vitro against drug resistant TB clinical isolates (n = 49). 94% of DR-TB stra...

Descripción completa

Detalles Bibliográficos
Autores principales: Mondal, Rajesh, Dusthackeer V. N., Azger, Kannan, Palaniyandi, Singh, Amit Kumar, Thiruvengadam, Kannan, Manikkam, Radhakrishnan, A. S., Shainaba, Balasubramanian, Mahizhaveni, Elango, Padmasini, Ebenezer Rajadas, Sam, Bharadwaj, Dinesh, Arumugam, Gandarvakottai Senthilkumar, Ganesan, Suresh, Kumar A. K., Hemanth, Singh, Manjula, Patil, Shripad, U. C. A., Jaleel, Doble, Mukesh, R., Balagurunathan, Tripathy, Srikanth Prasad, Kumar, Vanaja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983862/
https://www.ncbi.nlm.nih.gov/pubmed/36867599
http://dx.doi.org/10.1371/journal.pone.0282454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983862/
https://www.ncbi.nlm.nih.gov/pubmed/36867599
http://dx.doi.org/10.1371/journal.pone.0282454

Ejemplares similares